Search PubMed⌕ Search

Biomedical subjects

E V Gagaeva

Publications and source records attributed to E V Gagaeva.

9 recordsLinked to original sources
PubMed1991

[Pharmacokinetics of protegentin, a combined preparation].

Protegentin is a combined preparation in the form of ointment containing 0.1 per cent of gentamicin, 0.25 per cent of erythromycin and 0.1 per cent of protease C. Pharmacokinetic studies on the preparation were conducted. Protegentin and gentamicin ointment, currently manufactured in this country, were applied to the surface of experimental pure cutaneous wounds in guinea pigs in a dose of 1 g. It was shown that inspite of the same contents of gentamicin in the ointments, the mean maximum concentration of the antibiotic in the underlying muscular tissue after the protegentin application was somewhat higher than that after the use of the gentamicin ointment. The differences in the drug concentration maintained during the whole observation period of 24 hours. However, they were not statistically significant. The gentamicin concentrations in serum after the use of protegentin were also somewhat higher than those after application of the gentamicin ointment (the differences were not statistically significant). Still, in no case the concentrations reached the potentially toxic ones. The erythromycin concentrations in the muscular tissue were much higher than those in the blood.

Animals↗
PubMed1989

[Quantitative analysis of rifampicin and 25-desacetylrifampicin in the plasma using high performance liquid chromatography].

A procedure for determination of rifampicin and 25-desacetylrifampicin in plasma by HPLC was developed. The plasma proteins are precipitated by acetonitrile and the supernatant layer (50 microliters) is used for the assay under isocratic conditions on an analytical column 250 x 4.6 mm in size containing the reversed phase sorbent (C18). The size of the precolumn is 50 x 4.6 mm. An UV detector (at lambda 335 nm) is used. For preparing the mobile phase 630 ml of methanol and 370 ml of 0.058 M sodium nitrite solution are mixed. The flow rate of the mobile phase is 40.7 ml/min. The assay duration is about 10 min. The retention time is 9.6 min for rifampicin and 6.5 min for 25-desacetylrifampicin. The minimum detectable amount of the antibiotic and its metabolite is 0.10 micrograms/ml. The standard curves of rifampicin and 25-desacetylrifampicin are linear within the concentration ranges of 0.5-100 and 0.5-10 micrograms/ml respectively. The procedure is useful in studies on pharmacokinetics of rifampicin and 25-desacetylrifampicin.

Chromatography, High Pressure Liquid↗
PubMed1986

[Interrelations in the changes in the pharmacokinetics and nephrotoxic effect of sisomycin as affected by cefazolin].

The action of cefazolin on the pharmacokinetics and nephrotoxic effect of sisomicin was studied on Wistar rats. Sisomicin in doses of 12.5 and 25 mg/kg alone or in combination with cefazolin in doses of 90 and 360 mg/kg was administered intramuscularly to the animals daily for 16 days. It was shown that in both the doses cefazolin had no noticeable action on the level of the functional and morphological changes in the kidneys. Consequently, there were no significant changes in the levels of sisomicin in serum and the site of the nephrotoxic effect (cortical layer of the kidneys) and in the half-life of the aminoglycoside in the kidney cortical layer under the action of cefazolin. At the same time there was observed a marked individual variability of the levels of urea nitrogen and sisomicin in serum of the rats treated with the aminoglycoside alone or in combination with cefazolin. Analysis of the dependence of the nephrotoxic effect on concentration of sisomicin in serum after its use alone or in combination with cefazolin revealed that the changes in the individual intensity of the effect in all the cases were mainly induced by the changes in the sisomicin blood levels. Therefore, control of the blood levels of the aminoglycoside should provide prevention of the development of its nephrotoxic effect not only in monotherapy but also in the use of aminoglycosides in combination with cefazolin.

Animals↗
PubMed1985

[Decrease of sisomicin nephrotoxicity as affected by cephalothin: pharmacokinetic evaluation].

The effect of cephalothin on the nephrotoxicity and pharmacokinetics of sisomicin was studied on Wistar rats. Sisomicin was injected intramuscularly in doses of 12.5 and 25 mg/kg alone or in combination with cephalothin in a dose of 360 mg/kg once a day for 16 days. It was shown that the combined use of sisomicin and cephalothin resulted in less pronounced functional and morphological changes in the kidneys as compared to the use of sisomicin alone. The decrease in the nephrotoxic effect was accompanied by a decrease in the sisomicin concentration in the blood serum and the site of the nephrotoxic effect (the kidney cortical layer) and the period of the aminoglycoside half-life in the kidney cortical layer under the action of cephalothin. The analysis of the relation between the nephrotoxic effect and the concentration of sisomicin in the kidney cortical layer and blood serum demonstrates that the nephrotoxicity of the sisomicin combination with cephalothin is mainly due to a decrease in the aminoglycoside concentration in the zone of the nephrotoxic effect.

Animals↗